Sodium hyaluronate - Senju Pharmaceutical

Drug Profile

Sodium hyaluronate - Senju Pharmaceutical

Latest Information Update: 26 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Conjunctivitis; Corneal disorders

Most Recent Events

  • 24 Nov 2015 Preregistration for Conjunctivitis in Vietnam (Ophthalmic)
  • 24 Nov 2015 Preregistration for Corneal disorders in Vietnam (Ophthalmic)
  • 01 Jul 2002 Launched for Conjunctivitis in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top